WO2006093217A1 - Composition favorisant l'absorption du calcium et utilisation de celle-ci - Google Patents

Composition favorisant l'absorption du calcium et utilisation de celle-ci Download PDF

Info

Publication number
WO2006093217A1
WO2006093217A1 PCT/JP2006/303953 JP2006303953W WO2006093217A1 WO 2006093217 A1 WO2006093217 A1 WO 2006093217A1 JP 2006303953 W JP2006303953 W JP 2006303953W WO 2006093217 A1 WO2006093217 A1 WO 2006093217A1
Authority
WO
WIPO (PCT)
Prior art keywords
calcium
chain fatty
calcium absorption
dfa iii
composition
Prior art date
Application number
PCT/JP2006/303953
Other languages
English (en)
Japanese (ja)
Inventor
Hiroshi Hara
Chie Nakagawa
Norihiro Shigematsu
Original Assignee
National University Corporation Hokkaido University
Fancl Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation Hokkaido University, Fancl Corporation filed Critical National University Corporation Hokkaido University
Publication of WO2006093217A1 publication Critical patent/WO2006093217A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a calcium absorption promoting composition containing difructose anhydride III (DFA III) and a typical application technique thereof, and in particular, exhibits an action of promoting absorption of higher strength rumum.
  • DFA III difructose anhydride III
  • the present invention relates to a calcium absorption promoting composition capable of further reducing the volume of DFA III, and the use of foods, drinks, medicines and the like using the same.
  • osteoporosis in various bone diseases represented by osteoporosis, main causes include insufficient intake of calcium, decreased calcium absorption ability, postmenopausal hormone imbalance, and the like.
  • it is extremely important to acquire as much bone mass as possible from childhood to adolescence and increase the maximum bone mass, but in order to increase bone mass, It is important to consume more calcium.
  • difructose anno, ilide I ⁇ (hereinafter abbreviated as DFA III as appropriate), which is an indigestible disaccharide, has an action of promoting calcium absorption.
  • DFA III difructose anno, ilide I ⁇
  • Patent Document 1 proposes a calcium absorption enhancing composition that can be used for pharmaceuticals and foods and drinks. If this calcium absorption enhancing composition is taken orally, it is possible to efficiently absorb the little calcium taken.
  • Patent Document 1 Japanese Patent Laid-Open No. 11-43438 (published February 16, 1999) Disclosure of the Invention
  • the calcium absorption enhancing composition containing DFA III is an excellent composition capable of effectively promoting calcium absorption.
  • DFA III is a powerful force for which no effective industrial production technology has been known previously. Recently, by making Inurase II act on inulin, it is possible to efficiently produce high-purity DFA III. It became possible to manufacture. [0010] However, although industrial production has become possible, DFA III is currently expensive and costs more than several thousand yen per kilogram. Therefore, it is practically important to reduce the dose as much as possible, although it has become possible to use higher doses than before. As described in Patent Document 1, it has been clarified that there is no problem with the safety of DFA III. However, in general, as a problem common to indigestible oligosaccharides, oral intake is If it increases, diarrhea is likely to occur. If DFA III is to be used for calcium absorption promotion, such a problem does not need to be considered basically, but theoretically, it is possible to reduce the dose of DFA III. preferable.
  • the present invention has been made in view of the above problems, and its purpose is to enhance the absorption of calcium at a lower dose than before by enhancing the calcium absorption promoting action of DFA III.
  • the object is to provide a technique capable of further enhancing the action.
  • the calcium absorption promoting composition according to the present invention comprises difructose anhydride III (DFA III), a medium chain fatty acid and Z or a salt thereof or an ester thereof. It is characterized by containing.
  • DFA III difructose anhydride III
  • the medium-chain fatty acid and Z or a salt thereof or an ester thereof includes at least one of medium-chain fatty acid or a sodium salt thereof or an ester thereof. Can be used. Moreover, you may contain other components, such as an oligosaccharide. Furthermore, it is preferable that the medium chain fatty acid and Z or a salt thereof or an ester thereof are blended within a range of 1Z6 to 3 times by weight with respect to the DFA III.
  • the present invention includes a pharmaceutical composition containing the calcium absorption promoting composition.
  • This Examples of the pharmaceutical composition include foods and drinks, pharmaceuticals, and materials thereof, and particularly, the foods and drinks can preferably include nutritional supplements.
  • the pharmaceutical composition include, for example, calcium in addition to DFA III and medium chain fatty acid (including salts and esters thereof).
  • a composition used for calcium supplement that is, a calcium supplement composition can be listed.
  • the specific composition of the calcium supplement composition is not particularly limited, as a more preferable example, the weight ratio of DFA III, medium chain fatty acid (including salts and esters thereof), and calcium is Mention may be made of yarns in the range of 1-3: 0.5, 0.5-3: 0.2, respectively.
  • medium chain fatty acids including salts and esters
  • DFA I II which is already known to promote calcium absorption.
  • DFA III since the calcium absorption promoting action of DFA III can be further enhanced, it becomes possible to effectively promote calcium absorption with a small dose of DFA II I. Therefore, there is an effect that the practicality as a calcium absorption promoting composition can be further improved.
  • FIG. 1 is a graph showing the calcium content in the feces of rats fed with a diet containing the calcium absorption promoting composition according to the present invention in Examples.
  • FIG. 2 is a graph showing the pH of cecal contents in rats fed with a diet containing a calcium absorption promoting composition useful in the present invention.
  • FIG. 3 is a graph showing the amount of soluble ⁇ calcium in the cecum contents in rats fed with a diet containing a calcium absorption promoting composition useful in the present invention. The best form to do
  • the calcium absorption promoting composition useful in the present invention is difructose anhydride III.
  • the calcium absorption promoting composition may be simply abbreviated as “accelerating composition”.
  • DFA III is a disaccharide (di-D-fructoforanose-1,2 ': 2,3 dianhydride) in which two molecules of fructose are linked at 1, 2' and 2, 3 'and is indigestible .
  • the sweetness has about lZ 2 of sucrose and has a bifidobacteria growth action with high solubility in water. It has also been found by the present inventors that it has a calcium absorption promoting action (Patent Document 1).
  • the medium chain fatty acid is not particularly limited as long as it is a fatty acid having 6 to 12 carbon atoms.
  • cabronic acid hexanoic acid, carbon number 6
  • enanthic acid hebutanoic acid, carbon number 7
  • strong prillic acid octanoic acid, carbon number 8
  • pelargonic acid nonanoic acid, carbon number 9)
  • Saturated purine acids decanoic acid, carbon number 10
  • hedecanoic acid undecanoic acid, carbon number 11
  • lauric acid dodecanoic acid, carbon number 12
  • unsaturated fatty acids and the like within the range of these carbon numbers can also be suitably used.
  • fatty acids may have a linear structure! /, And may have a side chain or a branched chain.
  • salts and esters of these medium chain fatty acids can be used in the present invention.
  • the salt include sodium salts
  • examples of the ester include lower alcohol esters of the above-mentioned medium chain fatty acids and triglycerides (that is, fats and oils).
  • the medium chain fatty acid and Z or a salt thereof or an ester thereof may be used alone or in combination of two or more.
  • force prillic acid (C8), force puric acid (C10), and lauric acid (C12) are used alone, but of course, the medium chain fatty acids described above are not limited thereto.
  • a medium chain fatty acid salt or a medium chain fatty acid ester can be used in appropriate combination, a medium chain fatty acid and a medium chain fatty acid ester can be combined, or a medium chain fatty acid salt and a medium chain fatty acid ester can be combined. Or a combination of medium chain fatty acids and medium chain fatty acid salts.
  • fatty acids those having 2 to 6 carbon atoms are referred to as short chain fatty acids, those having 8 to 10 carbon atoms are referred to as medium chain fatty acids, and those having 12 or more carbon atoms are referred to as long chain fatty acids.
  • these fatty acid categories are not absolute.
  • any fatty acid or salt or ester thereof having at least 6 to 12 carbon atoms can be used as long as it can further enhance the calcium absorption promoting action of DFA III.
  • the fatty acid contained in general vegetable oil has about 18 carbon atoms, so if combined with DFA III can improve the absorption of calcium, the above range power of 6-12 is also lost. Even fatty acids (or their salts and esters) can be used in the present invention.
  • the calcium absorption promoting composition useful in the present invention may contain components other than the above-mentioned DFA III, medium chain fatty acid and Z or a salt or ester thereof.
  • Specific examples include various oligosaccharides. More specifically, malto-oligosaccharides such as fructo-rigosaccharide, raffinose, maltotriose, maltotetraose, maltopentaose, maltohexaose, etc .; isomalto-oligosaccharides; soybean oligosaccharides; Examples include, but are not limited to, cutin oligosaccharides; maltose; isolaffinose; palatinose; lactulose; trehalose; xylooligosaccharides; Among these, it is particularly preferable to use an oligosaccharide having a calcium absorption promoting action in combination.
  • the calcium absorption promoting composition according to the present invention includes calcium itself, in addition to the above DFA III, medium chain fatty acid (and Z or a salt or ester thereof), and other components such as oligosaccharides. Needless to say, it can also be contained.
  • one of the uses of the present invention is to improve the absorption efficiency of calcium contained in foods, which is not simply to increase the intake of calcium (i.e. Not to increase intake). Therefore, the promotion composition according to the present invention can be used in combination with a normal meal, or can be added to a normal meal and taken as it is. Therefore, the calcium content is not essential.
  • minerals other than calcium may be included! Since DFA III is known to promote absorption of not only calcium but also magnesium and iron, these minerals can be contained in addition to calcium. However, as will be described later, the absorption promoting action by using a medium chain fatty acid and Z or a salt or ester thereof is effective only for calcium.
  • the specific composition of the calcium absorption promoting composition according to the present invention is not particularly limited, but by combining medium chain fatty acid with DFA III, the calcium absorption promoting action of DFA III can be improved. Therefore, it is possible to reduce the content of DFA III than before.
  • the content of DFA III is preferably 1 to 3 times or more by weight with respect to calcium. It is more preferable to make it at least twice (of course, it may be outside this range depending on the application and composition). Even in the present invention, DFA III can be contained so as to achieve this amount, but the combined use of medium-chain fatty acids can improve the calcium absorption promotion effect of DFA III by about 2 to 3 times. (For example, about twice in the examples described later). Therefore, if it is only necessary to obtain the calcium absorption promoting effect to the same extent as in the case of DFA III alone, the content of DFA III in the promoting composition is 30 to 60% of that in the case of DFA III alone. It can be reduced to within the range.
  • composition of DFA I II can be ingested so that the composition according to the present invention can be ingested within the above preferred range based on the amount of calcium in the diet. If you like the content, set a range!
  • the content of the medium chain fatty acid and Z or a salt thereof or an ester thereof is not particularly limited, but is mixed with the DFA III within a range of 1Z6 to 3 times by weight. It is preferable. Medium chain fatty acids and Z or at least within this range
  • DFA III can exert an effect of reliably improving the calcium absorption promoting action of DFA III.
  • the weight ratio of DFA III in the promoting composition is within the range of 1-3%, and the medium chain fatty acid is within the range of 0.5-3.
  • a force that can give an example within the range of% is of course not limited to this.
  • the content of other components is particularly limited as long as an appropriate amount is set according to the use of the composition according to the present invention. It is not a thing.
  • the method for producing a calcium absorption promoting composition useful in the present invention is not particularly limited. Depending on the type and state of the promoting composition, each of the above components is made into a desired composition by a known method. What is necessary is just to mix
  • medium-chain fatty acids act jointly with DFA III, and enhance the calcium absorption promoting effect of the DFA III.
  • mineral absorption is not affected.
  • DFA III only the amount of calcium absorption can be increased.
  • medium chain fatty acids enhance the action that occurs in the small intestine among the calcium absorption promoting actions of DFA III. As a result, it becomes possible to efficiently absorb calcium even with intestinal strength.
  • DFA III has a special effect on the promotion of calcium absorption, and thus has a strong medium chain fatty acid and Z or a salt thereof. It is a combination.
  • a phospholipid for example, dipalmitoylphosphatidylethanolamine
  • Japanese Patent Laid-Open No. 9-20676 Japanese Patent Laid-Open No. 9-20676. See publication, date of publication: January 21, 1997 (1997).
  • medium-chain fatty acids and salts thereof, or esters thereof such action and effects have not been known so far, and as shown in the examples described later, medium-chain fatty acids can be used alone.
  • the administration of calcium alone does not promote the absorption of calcium.
  • the present invention has a major feature in using a medium chain fatty acid (or a salt or ester thereof) that has not been conventionally known in the technical field of promoting calcium absorption, It is capable of exhibiting superior effects that are more than simply combining DFA III with a medium chain fatty acid known as a nutritional component. [Use of the present invention]
  • the usage method of the calcium absorption promotion composition concerning this invention is not specifically limited, For example, it can use suitably as a nutrition composition for promoting absorption of calcium.
  • the organism to be used for the nutritional composition is not particularly limited and may be a living organism such as a sardine. Typically, it is a human, and other than this, domestic animals, experimental animals, etc. Can be mentioned.
  • the nutritional composition can be taken in any form. Therefore, the present invention includes foods and drinks containing the above-mentioned accelerating composition.
  • the food or drink that can be used in the present invention only needs to contain the above-mentioned accelerating composition, and therefore the type thereof is not particularly limited.
  • the type thereof is not particularly limited.
  • bread, rice cakes, rice, cereal foods, tofu or processed products (fried foods) Processed foods such as sake, medicinal liquor, etc .; seasonings such as mirin, vinegar, soy sauce, miso, dressing, mayonnaise, etc .
  • livestock farming foods such as koji, bacon, sausage; kamaboko, fried tempura Processed marine products such as hampen; fruit juice drinks, soft drinks, sports drinks, alcoholic drinks, teas, soy milk, etc .; soups such as potage soups; dairy products such as milk, yogurt, cheese, milk drinks; General foods such as, but not limited to.
  • these foods may be in the form of prepared foods, lunch boxes, or long-term preserved foods (canned foods, frozen foods, retort foods, etc.).
  • the method of adding the accelerating composition to these general foods is not particularly limited, and any known appropriate method can be adopted depending on the type of general food.
  • the above food and drink are prepared by applying the calcium absorption promoting composition according to the present invention to any food when cooking for hospital lunch under the control of a dietitian based on a doctor's meal.
  • the calcium absorption promoting composition according to the present invention may be liquid or solid such as powder or granule.
  • it may be an easily soluble preparation that can be used in alcoholic beverages and mineral water.
  • the food and drink may be processed into natural liquid foods, semi-digested nutritional foods or component nutritional foods, or drinks.
  • examples of the food and drink according to the present invention include functional foods used for specific uses other than general foods such as health foods and nutritional foods.
  • Specific examples include dietary supplements such as various supplements and foods for specified health use. In the case of supplements and the like, it can be used as it is by simply processing the above-mentioned accelerating composition into an appropriate shape, and a third component can be added as necessary.
  • the calcium absorption promoting composition useful in the present invention can be suitably used as a pharmaceutical product for promoting calcium absorption. Any route of administration of pharmaceuticals may be used, but oral administration is most preferred in view of the features and objects (problems) of the present invention.
  • the pharmaceutical dosage form according to the present invention may be any dosage form that can be conveniently administered orally.
  • Specific examples include liquid preparations such as suspensions, emulsions and syrups; solid preparations such as powders, granules, tablets, capsules, intestinal solvents, and troches. These dosage forms can be used alone or in combination.
  • additives that can be usually used in the field of pharmaceutical technology can be added depending on the purpose.
  • additives include excipients, binders, disintegrants, lubricants, corrigents, stabilizers and the like, but are not particularly limited.
  • excipients such as lactose, glucose, sucrose, and mannitol
  • disintegrants such as starch and sodium alginate
  • lubricants such as magnesium stearate and talc
  • Additives such as agents
  • binders such as polyvinyl alcohol, hydroxypropyl cellulose, gelatin
  • surfactants such as fatty acid esters
  • plasticizers such as glycerin
  • liquid preparations for example, sugars such as water, sucrose, sorbitol, and fructose; glycols such as polyethylene glycol and propylene glycol; oils such as sesame oil, olive oil, and soybean oil; p -Additives such as preservatives such as hydroxybenzoates can be contained in the product.
  • the present invention can be used in the form of supplements and the like, and such supplements are used in the same manner as in the above pharmaceutical preparations. It is possible to be.
  • the above-mentioned food and drink and pharmaceuticals can be used in combination with other vitamins, hormones, other nutrients, or trace elements or iron compounds.
  • other physiologically active ingredients, minerals, hormones, nutritional ingredients, flavoring agents, and the like can be mixed as necessary. This is preferable because it can have a taste of a favorite beverage.
  • the calcium absorption promoting composition according to the present invention can be suitably used as a food or drink, a pharmaceutical product, or a material thereof as described above. Therefore, in the present invention, a composition containing a component other than the basic components (DFA III, medium chain fatty acid and Z or salt, ester, other components) of the calcium absorption promoting composition is comprehensively defined as a pharmaceutical composition. Shall be called.
  • the main use of the present invention includes use of promoting absorption of calcium in a normal meal or efficiently supplementing calcium in combination with foods or preparations containing calcium. Therefore, among the above pharmaceutical compositions, preferred use forms of the present invention include nutritional supplements. Examples of the dietary supplement include the above supplements and drinks. Furthermore, the pharmaceutical composition according to the present invention can be effectively used as a drug for the prevention of osteoporosis.
  • the pharmaceutical composition when used as a dietary supplement or a pharmaceutical product, it may contain calcium in addition to the DFA III and the medium chain fatty acid (including salts and esters thereof). preferable. Accordingly, the pharmaceutical composition that is effective in the present invention can be suitably used as a calcium supplement composition.
  • the specific composition of the calcium supplement composition is not particularly limited. For example, it is preferably used as the calcium supplement composition within the range disclosed in [Composition of Accelerating Composition] described above. This comes out.
  • the blood was sacrificed under pentobarbital anesthesia.
  • the cecum was intentionally ligated at both ends, snap frozen in liquid nitrogen, and stored in a 40 ° C freezer.
  • the contents were diluted to 5 times volume with distilled water and homogenized, then 1.5 ml of the contents were ashed, and the calcium content was measured by atomic absorption spectrometry.
  • Fig. 2 shows the pH of the cecal contents
  • Fig. 3 shows the amount of soluble calcium in the cecal contents.
  • the pH of the caecal contents decreases when DFA III is added to the feed.
  • the amount of calcium soluble in the cecum also increased.
  • these figures were stronger than those with the addition of DFA III and medium chain fatty acids to the basic feed, but without any increase due to the addition of medium chain fatty acids (see Figure 3). ). Therefore, the addition of medium-chain fatty acids enhances the calcium absorption-promoting action by DFA III, indicating that the action occurs in the small intestine.
  • the calcium absorption promoting action of DFA III can be further improved. Therefore, it is possible to promote calcium absorption at a low dose. Therefore, the present invention can be effectively used in the fields of various functional foods and health foods, and can also be used as a preventive or therapeutic agent for bone-related diseases such as osteoporosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a pour objet de renforcer l'effet de l'anhydride de difructose III (ADF III) consistant à favoriser l'absorption du calcium. C'est à dire que l’invention fournit une composition favorisant l'absorption du calcium, laquelle comprend l’ADF III ainsi qu'un acide gras à chaîne moyennement longue et/ou son sel ou son ester.
PCT/JP2006/303953 2005-03-02 2006-03-02 Composition favorisant l'absorption du calcium et utilisation de celle-ci WO2006093217A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005058217A JP4759289B2 (ja) 2005-03-02 2005-03-02 カルシウム吸収促進組成物およびその利用
JP2005-058217 2005-03-02

Publications (1)

Publication Number Publication Date
WO2006093217A1 true WO2006093217A1 (fr) 2006-09-08

Family

ID=36941246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/303953 WO2006093217A1 (fr) 2005-03-02 2006-03-02 Composition favorisant l'absorption du calcium et utilisation de celle-ci

Country Status (2)

Country Link
JP (1) JP4759289B2 (fr)
WO (1) WO2006093217A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1143438A (ja) * 1997-07-29 1999-02-16 Nippon Beet Sugar Mfg Co Ltd カルシウム吸収亢進組成物
JP2002315503A (ja) * 2001-04-24 2002-10-29 Abbott Lab 骨石灰化促進用調合乳
WO2003090759A1 (fr) * 2002-04-26 2003-11-06 Fancl Corporation Composition contenant du difructose anhydride et utilisation de celle-ci
WO2004028279A1 (fr) * 2002-09-25 2004-04-08 Otsuka Pharmaceutical Co., Ltd. Composition sous forme de gel

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038097T2 (de) * 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1143438A (ja) * 1997-07-29 1999-02-16 Nippon Beet Sugar Mfg Co Ltd カルシウム吸収亢進組成物
JP2002315503A (ja) * 2001-04-24 2002-10-29 Abbott Lab 骨石灰化促進用調合乳
WO2003090759A1 (fr) * 2002-04-26 2003-11-06 Fancl Corporation Composition contenant du difructose anhydride et utilisation de celle-ci
WO2004028279A1 (fr) * 2002-09-25 2004-04-08 Otsuka Pharmaceutical Co., Ltd. Composition sous forme de gel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARA H.: "Promotive Effects of Nondigestible Saccharides on Calcium Absorption", FOODS & FOOD INGREDIENTS JOURNAL OF JAPAN, vol. 208, no. 1, 1 January 2003 (2003-01-01), pages 46 - 51, XP002996799 *
SUZUKI T. AND HARA H.: "Various non-digestible saccharides increase intracellular calcium ion concentration in rat small-intestinal enterocytes", BRITISH JOURNAL OF NUTRITION, vol. 92, no. 5, November 2004 (2004-11-01), pages 751 - 755, XP002999574 *

Also Published As

Publication number Publication date
JP2006241057A (ja) 2006-09-14
JP4759289B2 (ja) 2011-08-31

Similar Documents

Publication Publication Date Title
TWI337080B (en) Prebiotic compositions
CA2542652C (fr) Composition nutritionnelle contre les effets secondaires de la chimiotherapie ou radiotherapie
CN101938911B (zh) 富含蛋白的基于胶束酪蛋白的液体肠营养组合物
CN103347404B (zh) 包含甘油单酯和脂肪酸的营养型产品
CN104822279A (zh) 缓减压力症状的人乳寡糖
ES2625740T3 (es) Composiciones nutricionales que incluyen beta-hidroxi-beta-metilbutirato cálcico, fosfopéptido de caseina y proteina
CN102238947A (zh) 营养组合物
JP2009173634A (ja) ポリ−γ−グルタミン酸を含有する脂質吸収阻害剤
US20140378543A1 (en) Methods of producing and using nutritional and pharmaceutical compositions that include one or more active substances
CN112399799A (zh) 脂肪蓄积抑制用组合物
CN107616490A (zh) 一种儿童术后专用型临床营养配方及其制备方法
JP5749880B2 (ja) Ｄ−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤
WO2016050754A1 (fr) Composition nutritionnelle à faible teneur en acides gras à chaîne moyenne dans des proportions spécifiques, et ses utilisations
CN112120221A (zh) 高卡路里营养组合物
JP5156330B2 (ja) 脂肪組織重量減少剤
WO2017221845A1 (fr) Agent d'amélioration du débit sanguin, composition de gelée royale et procédé de production de la composition de gelée royale
WO2020218381A1 (fr) Composition favorisant la sécrétion de glp-1
JP4759289B2 (ja) カルシウム吸収促進組成物およびその利用
JP4915959B2 (ja) 砂糖様味質をもつ新規甘味料、その製造法および用途
JP7373918B2 (ja) 皮膚ガス放散調節用組成物
JP3285959B2 (ja) 長期療養患者用液状調製栄養食品
JP7216260B2 (ja) コプロコッカス属菌の増殖促進用組成物
JP2006199641A (ja) 鉄吸着性高分子物質及び鉄含有高分子物質ならびにこれらの製造方法
WO2023106078A1 (fr) Composition nutritionnelle
WO2023190809A1 (fr) Composition pour inhiber la production de cortisol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06715062

Country of ref document: EP

Kind code of ref document: A1